Biosignatures is set to lead the way using a pioneering in-vitro method of medical testing, with analysis through its unique patented software, Tiger. Testing is minimally invasive – for example allowing the replacement of a biopsy with a simple blood test – and therefore directly improves patient experience, is cost effective, relevant and viable for the medical environment, and can be applied to prognostic testing in addition to diagnostic use.
The company began in 2007, as an offshoot from Nonlinear Dynamics Ltd. The directors of Nonlinear now lead Biosignatures; Will Dracup CEO, Dave Bramwell CTO, and Duncan Barrie FD. Will Dracup has 27 years computing experience, 21 in life sciences. He founded Nonlinear in 1989, creating the initial products and leading it throughout its 25 year history. At Biosignatures, he is responsible for corporate strategy and commercialisation. Duncan Barrie is a Chartered Accountant and Fellow of the Securities Institute, with over 23 years experience in high-end companies, including corporate finance, flotation, fundraising, and equity/debt funding. Dr David Bramwell has 21 years computing experience. He obtained a First Class MSc in Microelectronics and Software Engineering, followed by a PhD in human visual perception. This was followed by postdoctoral work on human neural systems before joining Nonlinear in 2000. David and his research team designed Nonlinear’s flagship analysis product Progenesis™ (launched April 2001) and created the Company’s Tiger Technology and MPM platforms.
The ESRG Group funding will initially be channelled towards the first clinical trial of the first Biosignatures product. With this independent proof of blood testing capability achieved, the company will then expand, marketing existing products whilst simultaneously directing investment into the development of new ones. Biosignatures already has a commercial agreement with the Newcastle upon Tyne Healthcare Foundation Trust, which as well as being a major part of the NHS, is one of the biggest clinical research organisations in the UK. The company is also building a relationship with a major US corporation.
“Our introduction through Roland [Tate] was a fortuitous event for both companies. Biosignatures has a groundbreaking concept, technical knowledge to push it forward within the industry, and the business tenacity to guarantee success. The ESRG Group involvement is both a privilege and a sound financial investment”.
Executive Chairman, ESRG Group